APYX
Apyx Medical Corp
NASDAQ · Healthcare · Medical - Devices · US
$2.42
−5.10%Year over year
Reported trailing growth
- Revenue
- +25.6%
- EBITDA
- +84.9%
- EBIT
- +71.3%
- EPS
- +56.3%
- Free cash flow
- -10.1%
- Operating cash flow
- -8.8%
Forward estimates
Based on analyst estimates
- Revenue
- +8.3%
- EBITDA
- —
- EPS
- -34.7%
Three-year CAGR
- Revenue
- +5.9%
- EBITDA
- +72.7%
- EBIT
- +65.8%
- Net income
- +52.2%
- EPS
- +59.1%
- Free cash flow
- +51.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026